• Takahiro Tsuchiya, Yudai Hirano, Satoru Miyawaki, Satoshi Koizumi, Shotaro Ogawa, Seiei Torazawa, Hiroki Hongo, Hideaki Ono, and Nobuhito Saito.
• Department of Neurosurgery, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
• World Neurosurg. 2025 Feb 11: 123783123783.

ObjectivesThe mainstream approach for preventing cerebrovascular events in hemorrhagic or ischemic moyamoya disease (MMD) is surgical revascularization, and the indications for endovascular treatment (EVT) for MMD are limited. This systematic review aimed to evaluate the outcomes and complications associated with EVT in patients with MMD.MethodsA comprehensive search was conducted in June 2024 following the PRISMA guidelines in the PubMed, Cochrane Library, and Web of Science databases, for patients with MMD treated with EVT.ResultsSeventy-eight studies including 287 patients treated with EVT were identified. Target diseases included 255 aneurysms, 23 intracranial arterial stenoses, 4 extracranial arterial stenoses, 3 large vessel occlusions, and 2 dural arteriovenous fistulas. The outcomes of EVT for aneurysms in patients with MMD were comparable to those in patients without MMD. A significant association was observed between distal aneurysms and treatment failure (p < 0.001). The risk of re-rupture in the group that received conservative treatment for ruptured aneurysms was higher than that in the group that received radical treatment (p < 0.001). EVT for intracranial arterial stenosis carried a higher risk of recurrence, while that risk did not differ between the angioplasty and stent placement groups, with a median recurrence-free survival of 4 and 3.5 months respectively (p = 0.668).ConclusionsFor the patients with MMD, EVT of distal aneurysms would likely be unsuccessful because of the access difficulties. Furthermore, EVT for intracranial arterial stenosis often results in unsatisfactory treatment and has limited indications owing to the risk of complications.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

4 keywords...

hide…